• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Anti-infectives
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
August 11, 2022

Result of Broker Option / PDMR Dealings

Read More
August 04, 2022

INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022

Read More
August 03, 2022

Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m

Read More
July 11, 2022

FDA confirms response date for Type C Meeting as 29th August 2022

Read More
July 07, 2022

Initiation of research

Read More
June 28, 2022

2022 Result of ANNUAL GENERAL MEETING – all resolutions passed

Read More
June 27, 2022

Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients

Read More
June 21, 2022

Lanstead Capital Investors LP share holding update

Read More
June 01, 2022

Notice of AGM & Annual Report & Accounts

Read More
May 25, 2022

FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2021

Read More
May 04, 2022

UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION

Read More
April 13, 2022

UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study.

Read More
  • 1
  • 2
  • 3
  • …
  • 18
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved